Elena Ritsou

Elena Ritsou is an accomplished professional in the biotechnology and pharmaceutical sectors, currently serving as a Venture Partner at BGV, Chief Corporate Officer at VectorY, and Board Observer at Link Immunotherapeutics, all since October 2022. Previously, Elena held the position of Chief Business Officer at GammaDelta Therapeutics from May 2021 to July 2022 and advanced through various roles at Ipsen from April 2014 to May 2021, including Global Head of Oncology Business Development. Earlier experience includes a Director of Business Development role at Genzyme and a Senior Associate role at NEOVACS. Elena Ritsou holds a PhD in Immunology from Deutches Krebs Forschungs Zentrum, a Masters in Finance from HEC Paris, and a BSc in Molecular Biology and Immunology from The University of Edinburgh.